Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alexza Pharmaceuticals
Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
April 13th, 2008
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) announced that Bio*One Capital Pte. Ltd., one of the largest dedicated biomedical investment management companies in Asia, has committed to purchase $10 million of common stock in Alexza. The investment by Bio*One is being made in conjunction with Alexza's formation of Alexza Singapore Pte. Ltd., a wholly owned subsidiary. Alexza intends to initiate manufacturing operations for key components of Alexza's single-dose Staccato(R) device in Singapore. Alexza's single-dose Staccato devices are used in a majority of its current product candidates, including its lead program, AZ-004 (Staccato loxapine), which is in Phase 3 clinical testing for the...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-13)
|
